SynOx Therapeutics Strengthens Team with Appointment of Ton Logtenberg as Chairman and Ray Barlow as Chief Executive Officer
Plans to initiate a pivotal trial for patients suffering from Tenosynovial Giant Cell Tumours (TGCT)
Follows 37 M Series A investment to progress emactuzumab, a potentially best-in-class CSF-1R antibody licensed on an exclusive, worldwide basis from Ro... Biopharmaceuticals, Oncology, Personnel SynOx Therapeutics, emactuzumab, Tenosynovial Giant Cell Tumours
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer & Oncology | Pharmaceuticals